Electrochemical and surface plasmon insulin assays on clinical samples.
Electrochemical and surface plasmon insulin assays on clinical samples.
复制标题
对临床样品进行电化学和表面等离子体胰岛素测定。
DOI：
10.1039/c7an01872j
复制
发表时间：
2018-03-26
期刊：
影响因子：
--
通讯作者：
Krishnan S
中科院分区：
文献类型：
--
作者：
Singh V ;Krishnan S
糖尿病是一种复杂的免疫疾病，除了血糖控制外，还需要广泛的医疗护理。近年来，糖尿病的患病率，特别是1型糖尿病(T1D)的患病率从5%显著增加到10%，这已经影响了儿童和成人健康相关并发症的发生率。美国糖尿病协会2012年的统计数据显示，2,910万美国人(占总人口的9.3%)患有糖尿病，8,600万美国人(20岁≥年龄，2010年为7,900万人)患有前驱糖尿病。个性化血糖仪可通过轻松监测高毫摩尔血糖水平来管理糖尿病。相比之下，非葡萄糖糖尿病生物标志物在早期预测方面获得了相当大的关注，并提供了对糖尿病代谢途径的洞察，但由于其在血液中的水平极低，因此很难测量。同样，胰岛素泵、传感器和胰岛素监测系统具有相当大的生物医学意义，因为它们在管理糖尿病、糖尿病前期和胰腺疾病方面的需求不断增加。我们的实验室致力于开发电化学免疫传感器和表面等离子体微阵列，用于临床样本基质中胰岛素的微创测量。通过利用抗体或适配子作为胰岛素选择性生物识别元件与纳米材料相结合，我们展示了一系列选择性和临床敏感的电化学和表面等离子体免疫分析方法。本文综述了不同的检测胰岛素的电化学和表面等离子体免疫分析方法。考虑到糖尿病的诊断、治疗和管理以及胰岛素泵和监测设备的重要性，重点关注T1D(胰岛素缺乏状况)和2型糖尿病(胰岛素抵抗状况)，这篇关于胰岛素生物测定的综述是及时和重要的。
Diabetes is a complex immune disorder that requires extensive medical care beyond glycemic control. Recently, the prevalence of diabetes, particularly type 1 diabetes (T1D), has significantly increased from 5% to 10%, and this has affected the health-associated complication incidences in children and adults. The 2012 statistics by the American Diabetes Association reported that 29.1 million Americans (9.3% of the population) had diabetes, and 86 million Americans (age ≥20 years, an increase from 79 million in 2010) had prediabetes. Personalized glucometers allow diabetes management by easy monitoring of the high millimolar blood glucose levels. In contrast, non-glucose diabetes biomarkers, which have gained considerable attention for early prediction and provide insights about diabetes metabolic pathways, are difficult to measure because of their ultra-low levels in blood. Similarly, insulin pumps, sensors, and insulin monitoring systems are of considerable biomedical significance due to their ever-increasing need for managing diabetic, prediabetic, and pancreatic disorders. Our laboratory focuses on developing electrochemical immunosensors and surface plasmon microarrays for minimally invasive insulin measurements in clinical sample matrices. By utilizing antibodies or aptamers as the insulin-selective biorecognition elements in combination with nanomaterials, we demonstrated a series of selective and clinically sensitive electrochemical and surface plasmon immunoassays. This review provides an overview of different electrochemical and surface plasmon immunoassays for insulin. Considering the paramount importance of diabetes diagnosis, treatment, and management and insulin pumps and monitoring devices with focus on both T1D (insulin-deficient condition) and type 2 diabetes (insulin-resistant condition), this review on insulin bioassays is timely and significant.
登录
查看更多内容
影响因子：
9.8
作者：
GOETZ, FC;FRENCH, LR;CLEMENTS, JP
通讯作者：
CLEMENTS, JP
影响因子：
16.2
作者：
Lee, S;Bacha, F;Arslanian, SA
通讯作者：
Arslanian, SA
影响因子：
8.4
作者：
Arvinte, Adina;Westermann, A. Caroline;Virtanen, Vesa
通讯作者：
Virtanen, Vesa
影响因子：
12.6
作者：
Gerasimov, Jennifer Y.;Schaefer, Cody S.;Lai, Rebecca Y.
通讯作者：
Lai, Rebecca Y.
影响因子：
12.6
作者：
Gobi, K. Vengatajalabathy;Iwasaka, Hiroyuki;Miura, Norio
通讯作者：
Miura, Norio